| Alopecias in lupus erythematosus JSS Concha, VP Werth Lupus science & medicine 5 (1), e000291, 2018 | 59 | 2018 |
| The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria JSS Concha, M Tarazi, CJ Kushner, RG Gaffney, VP Werth British Journal of Dermatology 180 (5), 1001-1008, 2019 | 41 | 2019 |
| Treatment of autoimmune bullous disorders in pregnancy CJ Kushner, JSS Concha, VP Werth American Journal of Clinical Dermatology 19 (3), 391-403, 2018 | 30 | 2018 |
| Safety, tolerability, and activity of ALXN1830 targeting the neonatal Fc receptor in chronic pemphigus VP Werth, DA Culton, JSS Concha, JS Graydon, LJ Blumberg, J Okawa, ... Journal of Investigative Dermatology 141 (12), 2858-2865. e4, 2021 | 29 | 2021 |
| Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis JSS Concha, JF Merola, D Fiorentino, VP Werth Journal of the American Academy of Dermatology 78 (4), 769-775. e2, 2018 | 28 | 2018 |
| Developing classification criteria for skin‐predominant dermatomyositis: the Delphi process JSS Concha, S Pena, RG Gaffney, B Patel, M Tarazi, CJ Kushner, ... British Journal of Dermatology 182 (2), 410-417, 2020 | 27 | 2020 |
| The effects of immunostimulatory herbal supplements on autoimmune skin diseases CE Bax, S Chakka, JSS Concha, M Zeidi, VP Werth Journal of the American Academy of Dermatology 84 (4), 1051-1058, 2021 | 25 | 2021 |
| Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis S Ahmed, S Chakka, J Concha, R Krain, R Feng, VP Werth British Journal of Dermatology 182 (4), 949-954, 2020 | 25 | 2020 |
| Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial VP Werth, E Hejazi, SM Pena, J Haber, M Zeidi, N Reddy, J Okawa, ... Journal of Investigative Dermatology 142 (10), 2651-2659. e1, 2022 | 24 | 2022 |
| The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review S Chakka, RL Krain, JSS Concha, BF Chong, JF Merola, VP Werth Annals of Translational Medicine 9 (5), 2021 | 21 | 2021 |
| Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus S Chakka, RL Krain, S Ahmed, JSS Concha, R Feng, JT Merrill, VP Werth Journal of the American Academy of Dermatology 84 (6), 1562-1567, 2021 | 19 | 2021 |
| FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis VP Werth, E Hejazi, SM Pena, JS Haber, J Okawa, R Feng, K Gabre, ... Annals of the Rheumatic Diseases 77 (Suppl 2), 763-764, 2018 | 19 | 2018 |
| Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric … CJ Kushner, M Tarazi, RG Gaffney, R Feng, K Ardalan, ... British Journal of Dermatology 180 (1), 165-171, 2019 | 18 | 2019 |
| Autoimmune skin disease exacerbations following COVID-19 vaccination G Sprow, M Afarideh, J Dan, R Feng, E Keyes, M Grinnell, J Concha, ... Frontiers in immunology 13, 899526, 2022 | 16 | 2022 |
| Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM S Maddukuri, J Patel, DA Diaz, KL Chen, M Wysocka, C Bax, Y Li, ... Arthritis research & therapy 24 (1), 12, 2022 | 16 | 2022 |
| Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A report from the 4th International Conference on Cutaneous Lupus Erythematosus An ongoing need for international … JSS Concha, A Patsatsi, A Marshak-Rothstein, M Liu, AA Sinha, LA Lee, ... The Journal of investigative dermatology 139 (2), 270, 2019 | 16 | 2019 |
| SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001 VP Werth, B Patel, JS Concha, J Okawa, D Pearson, E Hejazi, R Feng, ... Annals of the Rheumatic Diseases 77 (Suppl 2), 1111-1112, 2018 | 14 | 2018 |
| SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001 VP Werth, B Patel, JS Concha, J Okawa, D Pearson, E Hejazi, R Feng, ... Annals of the Rheumatic Diseases 77 (Suppl 2), 1111-1112, 2018 | 13 | 2018 |
| Cutaneous lupus concerns from the patient perspective: a qualitative study D Yan, D Zamalin, S Chakka, R Krain, J Concha, R Feng, S Ahmed, ... Lupus science & medicine 8 (1), e000444, 2021 | 8 | 2021 |
| A phase 2 study of safety and efficacy of anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis VP Werth, E Hejazi, SM Pena, JS Haber, J Okawa, R Feng Arthritis Rheumatol 69 (suppl 10), 2017 | 6 | 2017 |
